Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 2
1973 11
1974 15
1975 35
1976 38
1977 56
1978 28
1979 40
1980 40
1981 56
1982 46
1983 47
1984 48
1985 51
1986 57
1987 63
1988 33
1989 38
1990 45
1991 54
1992 41
1993 59
1994 68
1995 62
1996 45
1997 80
1998 71
1999 64
2000 97
2001 94
2002 83
2003 97
2004 108
2005 130
2006 133
2007 129
2008 128
2009 119
2010 105
2011 102
2012 103
2013 97
2014 70
2015 37
2016 23
2017 27
2018 27
2019 29
2020 37
2021 34
2022 24
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

2,944 results

Results by year

Filters applied: . Clear all
Page 1
Disodium etidronate (EHDP).
Evans RA. Evans RA. Med J Aust. 1984 Feb 4;140(3):182-3. doi: 10.5694/j.1326-5377.1984.tb103980.x. Med J Aust. 1984. PMID: 6420653 No abstract available.
Etidronate disodium in the treatment of Paget's disease of bone.
Krane SM. Krane SM. Ann Intern Med. 1982 May;96(5):619-25. doi: 10.7326/0003-4819-96-5-619. Ann Intern Med. 1982. PMID: 6280538 Review.
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical …
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonate …
History of etidronate.
Watts NB, Chesnut CH 3rd, Genant HK, Harris ST, Jackson RD, Licata AA, Miller PD, Mysiw WJ, Richmond B, Valent D. Watts NB, et al. Bone. 2020 May;134:115222. doi: 10.1016/j.bone.2020.115222. Epub 2020 Jan 3. Bone. 2020. PMID: 31911206
Etidronate is a non-nitrogen-containing bisphosphonate. Because it binds with calcium and inhibits crystal formation and dissolution, it was considered by Procter & Gamble as an additive to toothpaste (to prevent build-up of tartar) and detergent (to bind calcium and i …
Etidronate is a non-nitrogen-containing bisphosphonate. Because it binds with calcium and inhibits crystal formation and dissolution, …
Etidronate disodium in the management of malignancy-related hypercalcemia.
Hasling C, Charles P, Mosekilde L. Hasling C, et al. Am J Med. 1987 Feb 23;82(2A):51-4. doi: 10.1016/0002-9343(87)90487-6. Am J Med. 1987. PMID: 3103436 Clinical Trial.
To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate, 7.5 mg/k …
To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 …
Etidronate disodium in postmenopausal osteoporosis.
Heaney RP, Saville PD. Heaney RP, et al. Clin Pharmacol Ther. 1976 Nov;20(5):593-604. doi: 10.1002/cpt1976205593. Clin Pharmacol Ther. 1976. PMID: 824086
Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10%, and effective retained dose was approximately …
Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium …
Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Hasling C, Charles P, Mosekilde L. Hasling C, et al. Eur J Clin Invest. 1986 Oct;16(5):433-7. doi: 10.1111/j.1365-2362.1986.tb01019.x. Eur J Clin Invest. 1986. PMID: 3100312 Clinical Trial.
The efficacy of intravenous etidronate disodium in controlling hypercalcaemia of malignancy was evaluated in a double blind, placebo-controlled study. ...The renal calcium excretion decreased significantly in the etidronate group, but not in the placebo group …
The efficacy of intravenous etidronate disodium in controlling hypercalcaemia of malignancy was evaluated in a double blind, p …
Investigation of Physical Properties of Disodium Etidronate Tetrahydrate and Application of Phosphorus K-Edge X-Ray Absorption Near-Edge Structure Spectroscopy.
Ito N, Hashizuka T, Ito M, Suzuki H, Noguchi S. Ito N, et al. Pharm Res. 2021 Dec;38(12):2147-2155. doi: 10.1007/s11095-021-03151-4. Epub 2021 Dec 17. Pharm Res. 2021. PMID: 34919171
PURPOSE: Disodium etidronate is a bisphosphonate, compounds that are widely used in the treatment of bone disorders such as osteoporosis and Paget's disease. ...CONCLUSIONS: Acquired information about physical properties are crucial for manufacturing of solid formul …
PURPOSE: Disodium etidronate is a bisphosphonate, compounds that are widely used in the treatment of bone disorders such as os …
Comparison of the physical properties of disodium etidronate amorphous forms prepared by different manufacturing methods.
Ito N, Hashizuka T, Ito M, Suzuki H, Noguchi S. Ito N, et al. Int J Pharm. 2023 Mar 25;635:122723. doi: 10.1016/j.ijpharm.2023.122723. Epub 2023 Feb 15. Int J Pharm. 2023. PMID: 36803929
Amorphous forms of disodium etidronate were prepared by three manufacturing methods, heat drying, freeze drying, and anti-solvent precipitation, and the effects of these methods on the physical properties of disodium etidronate amorphous forms were eva …
Amorphous forms of disodium etidronate were prepared by three manufacturing methods, heat drying, freeze drying, and anti-solv …
Etidronate and osteoarthritis.
Forys VA. Forys VA. JAMA. 1991 Jun 5;265(21):2807. JAMA. 1991. PMID: 1903460 No abstract available.
Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients.
Stover SL, Niemann KM, Miller JM 3rd. Stover SL, et al. J Bone Joint Surg Am. 1976 Jul;58(5):683-8. J Bone Joint Surg Am. 1976. PMID: 819446 Clinical Trial.
Disodium etidronate was used in a clinical trial with four patients to study its effectiveness in preventing the recurrence of mineralization after surgical removal of heterotopic ossification. ...After discontinuation of drug therapy, recurrence was variable but le …
Disodium etidronate was used in a clinical trial with four patients to study its effectiveness in preventing the recurrence of …
2,944 results